Literature DB >> 8628132

Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory.

J R Carapetis1, D R Wolff, B J Currie.   

Abstract

OBJECTIVE: To describe the epidemiological and clinical features of acute rheumatic fever and rheumatic heart disease in the Top End of the Northern Territory.
METHODS: A retrospective review (in some instances as far back as the 1960s) of all cases of known or suspected acute rheumatic fever or rheumatic heart diseases, with prospective validation of clinical status where necessary. Cases were ascertained from hospital and community medical clinic records and medical staff; and from records and health staff of 10 rural communities.
RESULTS: Three hundred and eighty-six revised Jones criteria-confirmed episodes of acute rheumatic fever were documented in 249 individuals (99% Aboriginal). The annual incidence of confirmed acute rheumatic fever between 1989 and 1993 was 254 per 100,000 Aboriginal people aged 5 to 14 years. A more accurate estimate of 651 per 100,000 came from 10 rural communities with more complete information. As of 1995, there were 286 people living with established rheumatic heart disease (95% Aboriginal). The point prevalence of rheumatic heart disease among Aboriginal people was 9.6 per 1000, with a rate of 24 per 1000 in one large rural community. Sydenham's chorea was common, and associated with later rheumatic heart disease in 49% of cases. There was a preponderance of females with acute rheumatic fever, rheumatic heart disease and chorea.
CONCLUSIONS: In Aboriginal people in rural northern Australia the incidence of acute rheumatic fever is higher than that reported anywhere in the world, and the prevalence of rheumatic heart disease is among the highest in the world. While continuing attention must be paid to alleviating the causes of these diseases of poverty, immediate action is needed to improve diagnosis of acute rheumatic fever, adherence to secondary benzathine penicillin prophylaxis regimens, and follow-up of rheumatic heart disease cases.

Entities:  

Mesh:

Year:  1996        PMID: 8628132     DOI: 10.5694/j.1326-5377.1996.tb122012.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  41 in total

1.  Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.

Authors:  E R Brandt; T Teh; W A Relf; R I Hobb; M F Good
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Echocardiographic screening for rheumatic heart disease-some answers, but questions remain.

Authors:  Marc G W Rémond; Graeme P Maguire
Journal:  Transl Pediatr       Date:  2015-07

3.  Antistreptokinase antibodies: implications for thrombolysis in a region with endemic streptococcal infection.

Authors:  N Blackwell; A Hollins; G Gilmore; R Norton
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

Review 4.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  The prospect of vaccination against group A beta-hemolytic streptococci.

Authors:  Karen L Kotloff
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 6.  Prevention and treatment of rheumatic heart disease in the developing world.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Nat Rev Cardiol       Date:  2009-09-15       Impact factor: 32.419

7.  Group A streptococcal Vir types are M-protein gene (emm) sequence type specific.

Authors:  D L Gardiner; A M Goodfellow; D R Martin; K S Sriprakash
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

8.  Distribution and antigenicity of fibronectin binding proteins (SfbI and SfbII) of Streptococcus pyogenes clinical isolates from the northern territory, Australia.

Authors:  A M Goodfellow; M Hibble; S R Talay; B Kreikemeyer; B J Currie; K S Sriprakash; G S Chhatwal
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 9.  Sex Differences in Pediatric Rheumatology.

Authors:  Marco Cattalini; Martina Soliani; Maria Costanza Caparello; Rolando Cimaz
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

10.  Streptococcal collagen-like protein A and general stress protein 24 are immunomodulating virulence factors of group A Streptococcus.

Authors:  James A Tsatsaronis; Andrew Hollands; Jason N Cole; Peter G Maamary; Christine M Gillen; Nouri L Ben Zakour; Malak Kotb; Victor Nizet; Scott A Beatson; Mark J Walker; Martina L Sanderson-Smith
Journal:  FASEB J       Date:  2013-03-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.